#Australia #Melbourne #CT Imaging #4DMedical #CTVQ™

4DMedical Receives CE Mark for Revolutionary CTVQ™ Technology

4DMedical Limited (ASX:4DX), the leading entity in cardiothoracic imaging software, has officially received CE Mark certification for its groundbreaking imaging technology, CTVQ™. This certification enables the rapid commercial launch of CTVQ™ across the European Union, one of the largest markets for respiratory imaging in the world.

The CTVQ™ Technology

CTVQ™ uniquely amalgamates the anatomical precision of CT scans with functional ventilation-perfusion mapping derived from routine non-contrast CT. This technology provides medical professionals with invaluable quantitative insights regarding regional lung functionality without relying on radiotracers. This innovation signifies a monumental shift in how pulmonary conditions can be evaluated, allowing clinicians to visualize ventilation and perfusion at a granular level.

The functionality of CTVQ™ is especially crucial as it addresses the limitations of traditional imaging techniques that predominantly focus on structural aspects of pulmonary diseases. By offering both anatomical clarity and functional data, CTVQ™ facilitates a deeper understanding of pulmonary diseases, which are primarily characterized by ventilation and perfusion anomalies.

Expanding into Europe

With the European market poised for the adoption of advanced cardiothoracic imaging technologies, 4DMedical recognizes the immense potential CTVQ™ holds in this region. Europe boasts a population exceeding 450 million, coupled with a robust hospital-based imaging infrastructure and a substantial number of existing CT scanners.

4DMedical's estimates indicate that around 400,000 nuclear VQ scans are conducted annually within Europe, highlighting the pressing clinical demand for innovative imaging solutions. Andreas Fouras, the Managing Director and CEO of 4DMedical, emphasized the significance of CE Mark certification, which aptly positions the company to grow within one of the world’s most sophisticated healthcare markets. "Our CE Mark certification is a game-changer that amplifies our mission to enhance pulmonary assessments globally," Fouras stated.

Funding for Growth Initiatives

In conjunction with the CE Mark announcement, 4DMedical has secured A$83 million through a private placement that saw participation from selected institutional investors. This funding will be instrumental in supporting the growth trajectory of CTVQ™, particularly as the company implements its expansion strategy across Europe.

4DMedical continues to build momentum in the United States, already deploying CTVQ™ in six prominent academic medical centers, including institutions like Stanford and the Cleveland Clinic. The early adoption of this technology in major healthcare settings reflects the keen interest from leading radiology and pulmonary teams in enhancing diagnostic capabilities.

A Shared Clinical Need

The universal clinical demand for CTVQ™ technology is undeniable, as healthcare systems worldwide face common challenges posed by the constraints of nuclear VQ scanning—namely, the reliance on radiotracers, limited accessibility, and complications in operational procedures. Europe, recognized for its clinical expertise, rigorous research, and advanced imaging infrastructure, is well-equipped to champion the adoption of CTVQ™ and its role in forming evidence-based practices.

4DMedical is now fortifying its plans for commercial engagement, aiming to collaborate with leading hospitals and clinicians throughout Europe to establish avenues for adoption, research, and evaluation of CTVQ™.

About 4DMedical

4DMedical Limited is a pioneering global medical technology enterprise focused on creating advanced software-based imaging solutions. By incorporating proprietary algorithms and artificial intelligence, their platform delivers depth in quantitative insights from routine clinical imaging, aiding medical professionals in assessing lung functions and managing cardiopulmonary diseases. 4DMedical's tools are designed to seamlessly integrate into current clinical workflows, yielding actionable, patient-centric information that fosters better decision-making and operational efficiencies across diverse respiratory conditions.

For more information, visit 4DMedical.